AXIM Biotechnologies (OTCQB:AXIM) has completed point-of-care clinical trials on its ImmunoPass rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies.

The test aims to help understand COVID-19 immunity, validate vaccine’s effectiveness and estimate how long the vaccine will be effective in patients.

Study findings showed that operators found ImmunoPass easy to use and that they encountered no issues in using the test to measure participants’ COVID-19 neutralizing antibodies, AXIM said.

The company is currently working with Empowered Diagnostics to compile the study results and file an Emergency Use Application (EUA) with the U.S. FDA for the use of ImmunoPass in detecting COVID-19 neutralizing antibodies in whole blood at point-of care locations.